Evidence map›Paper›PMID 39971624›Full record

ArticleThe journal of pathology. Clinical research2025

Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cells.

Burles A Johnson, Vamsi Parimi, Sonia Kamanda, David C Corney, Woonyoung Choi, Jean Hoffman-Censits, Max Kates, David J McConkey, Noah M Hahn, Andres Matoso

Abstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Burles A JohnsonDepartment of Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Vamsi ParimiDepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Sonia KamandaDepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
David C CorneyMultiomics, Azenta Life Sciences, South Plainfield, New Jersey, USA.
Woonyoung ChoiDepartment of Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, Maryland, USA.
Jean Hoffman-CensitsDepartment of Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Max KatesDepartment of Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
David J McConkeyDepartment of Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Noah M HahnDepartment of Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Andres MatosoDepartment of Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.ORCID 0000-0003-0990-1115

Funding

Opportunities for Pathology Trainees in Cancer ResearchT32CA193145 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A., EBERHART, CHARLES G · 2015 to 2025
$2.6M
AOU NIH HHS CA220769NCI NIH HHS T32 CA193145
6 · The paper itself

Abstract

Sarcomatoid urothelial carcinoma (SUC) is a rare histologic subtype with poor prognosis. While there is known intra-tumoral heterogeneity between individual SUC tumors, the relationship between sarcomatoid and conventional urothelial carcinoma (CUC) within the same patient is poorly understood. The objective of this study was to identify differences between the sarcomatoid and CUC tumor microenvironment components that may drive this aggressive phenotype. Using tissue microarrays from eight patient tumors with mixed CUC and SUC, we examined paired CUC, mixed urothelial carcinoma (UC) regions, and SUC using the Nanostring Digital Spatial Profiling platform. We found SUC and mixed UC had higher levels of stromal cells, predominately macrophages and fibroblasts, when compared with CUC within the same tumor. CD14, CD163, and transforming growth factor-beta levels were significantly higher in SUC than in CUC. Immunohistochemical analysis revealed consistently moderate to strong expression of CD163-positive antigen-presenting cells (APCs) in SUC regions, whereas CD68-positive APC expression was generally absent. Thus, in mixed histology SUC, the SUC component preferentially expressed CD163-positive APCs and fibroblasts compared to the CUC component. As CD163-positive APCs and fibroblasts are known to be tumor-promoting and immune-suppressive, this infiltration may contribute to epithelial to mesenchymal transition and other aggressive properties of SUC.

Indexed as

Antigen-Presenting CellsAntigens, CDAntigens, Differentiation, MyelomonocyticCarcinoma, Transitional CellReceptors, Cell SurfaceUrinary Bladder NeoplasmsUrotheliumAgedBiomarkers, TumorCD163 AntigenFemaleHumansMacrophagesMaleMiddle AgedTumor MicroenvironmentAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkers, TumorCD163 AntigenReceptors, Cell Surfacebladder cancerCD163macrophagesarcomatoid carcinoma

Identifiers

PMID39971624
PMCPMC11839278

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.